Director/PDMR Shareholding

RNS Number : 7061G
Renalytix AI PLC
08 November 2018
 

Renalytix AI plc

("Renalytix" or the "Company")

 

Director / PDMR shareholding

 

Renalytix AI plc (AIM: RENX), a developer of artificial intelligence ("AI") enabled clinical diagnostic solutions for kidney disease, announces that it was yesterday notified that on 6 November 2018 the following PDMR undertook a transaction in the ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares"), at a price of 120 pence per Ordinary Share:

 

 

 

 

 

 Number of Ordinary Shares bought

Resultant Interest in Ordinary Shares

Resultant Interest in Ordinary Shares (%)

 

James McCullough

Chief Executive Officer

 

 

16,150

               

2,870,110

5.33

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

James R. McCullough

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Renalytix AI plc

b)

 

LEI

 

 

   213800NTOH3FK3WER551

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 0.25 pence each

 

 

Identification code

GB00BYWL4Y04

 

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

 

 

120 pence

16,150

 

 

 

 

 

 

d)

 

Aggregated information

n/a

 

 

- Aggregated volume

 

 

 

- Price

 

 

 

e)

 

Date of the transaction

 

 

06 November 2018

f)

 

Place of the transaction

 

 

London Stock Exchange

 

 

For further information, please contact:

 

Renalytix AI plc 

www.renalytixai.com

James McCullough, CEO

Via Walbrook PR or Tel: +1 646 397 3970

 

 

 

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / James White / George Tzimas (Corporate Finance)
Tom Salvesen
/ Ross Penney (Corporate Broking)

 

 

 

 

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or renalytix@walbrookpr.com

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

     

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHFKODPBBDBPDK
UK 100

Latest directors dealings